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54
The bacterial pathogen Vibrio cholerae causes the severe human diarrheal disease cholera, a 55 potentially fatal illness characterized by rapid-onset of fluid loss and dehydration. Recent 56 estimates place the global burden of cholera at ~3 million cases per year, and over 1.3 billion 57 people are at risk of this disease [1] . V. cholerae proliferates in the small intestine and produces 58 cholera toxin (CT), which leads to water and electrolyte secretion into the intestinal lumen [2] . 59
The O1 serogroup of V. cholerae causes virtually all epidemic cholera. This serogroup includes 60 two serotypes, Inaba and Ogawa, whose LPS structures differ by a single methyl group on the 61 terminal O-antigen sugar [3] . Serologic and epidemiologic studies have established the existence 62 of extensive serotype cross-reactivity and -protectivity, although immunogenicity and protection 63 is highest to the homologous serotype [4] [5] [6] [7] . Toxigenic O1 strains are divided into two major 64 biotypes, classical and El Tor, but the former has not been isolated in over a decade and is thought 65 to be extinct [8] . Ongoing evolution of El Tor V. cholerae has given rise to "atypical El Tor" (AET) 66 strains, which are distinguishable from earlier strains by a variety of features, including the 67 expression of a non-canonical ctxB allele, that may impact disease severity in afflicted patients 68 [4, 9, 10] . AET strains, such as the strain responsible for the 2010 Haitian cholera epidemic, are 69 thought to be the globally dominant cause of cholera [10] [11] [12] . Currently, serogroup O139 isolates 70 4 only cause sporadic disease [13] . Notably, antibodies (or immune responses) targeting the O1 O-71 antigen do not protect against O139 challenge and vice versa [14] [15] [16] . 72
Oral cholera vaccines (OCVs) have recently become widely accepted as a tool for cholera control 73 [17] . Vaccines are a potent method to combat cholera due to their ability to both directly and 74 indirectly reduce disease and transmission [18] . Killed multivalent whole-cell OCVs, such as 75 Shancol, have shown promise both to prevent disease in endemic regions and as reactive agents 76 to limit cholera during epidemics [19] . However, killed OCVs tend to be less effective at eliciting 77 protective immunity in young children (<5 years old), who are most susceptible to cholera [20, 21] . 78
Additionally, these vaccines typically require two doses over the span of several weeks, although 79 recent studies suggest that a single dose may still lead to moderate protection [20, 22, 23] . 80
There is no live-attenuated OCV licensed for use in cholera-endemic regions. The only clinically 81 available live-attenuated OCV is Vaxchora (CVD103-HgR), which is derived from a classical O1 82
Inaba V. cholerae strain and was approved by the US FDA in 2017 for use in travelers [24] . In 83 contrast to killed OCVs, live vaccines, such as CVD103-HgR and the El Tor-derived vaccine Peru-84 15, elicit more potent immune responses in young children [25, 26] , potentially because they more 85 closely mimic natural infection than killed OCVs. In particular, live vaccines can produce antigens 86 in vivo that are not expressed in the in vitro growth conditions used to prepare killed vaccines; 87 furthermore, the inactivation processes used to formulate killed vaccines can destroy antigenic 88 epitopes [27] . 89
In addition to the requirement for multiple doses of some OCVs for optimal protection, all current 90 live and killed OCVs are thought to be accompanied by a post-vaccination lag in protection during 91 induction of anti-V. cholerae adaptive immunity. The shortest reported time to protective efficacy 92 is 8 days post-vaccination, a delay that could hamper reactive vaccination campaigns designed 93 to limit the spread of cholera outbreaks [28] . We recently created HaitiV, a new live-attenuated 94 OCV candidate derived from an AET O1 Ogawa V. cholerae clinical isolate from the 2010 Haiti 95 5 cholera outbreak. HaitiV harbors many genetic alterations that render it avirulent and resistant to 96 reversion while preserving its robust capacity for colonization of the small intestine [29] . In an 97 infant rabbit model of cholera [30] , intestinal colonization with HaitiV conferred protection against 98 lethal wild-type (WT) V. cholerae challenge within 24 hours of vaccination, a timescale 99 inconsistent with the development of adaptive immunity and suggestive of a "probiotic"-like 100 mechanism of protection. Here, using a mouse model of V. cholerae intestinal colonization, we 101
show that oral administration of HaitiV to female mice elicits serum vibriocidal antibodies and 102 protects their pups from lethal challenge with virulent V. cholerae. Thus, HaitiV has the potential 103 to provide rapid probiotic-like protection as well as to elicit long-lasting immune protection from 104 cholera. 105
106
Methods
107
Bacterial strains and growth conditions
108
All bacteria were grown in Luria-Bertani (LB) broth supplemented with the relevant chemicals at 109 the following concentrations: streptomycin (Sm, 200µg/mL), kanamycin (200µg/mL), carbenicillin 110 (Cb, 50µg/mL), sulfamethoxazole/trimethoprim (SXT, 80 and 16µg/mL) and 5-bromo-4-chloro-3-111 indolyl-β-d-galactopyranoside (X-gal, 60µg/mL). For growth on plates, LB + 1.5% agar was used. 
Oral immunization regimen
Quantification of vibriocidal responses
140
Vibriocidal antibody quantification was performed by complement-mediated cell lysis using 141 PIC018 (Inaba) or PIC158 (Ogawa) V. cholerae as the target strain as previously described [31] . 142
Seroconversion was defined as ≥4x increase in titer over the baseline measurement. The7 characterized mouse monoclonal antibody 432A.1G8.G1.H12 targeting V. cholerae O1 OSP was 144 used as a positive control for the vibriocidal assay. Titers are reported as the dilution of serum 145 causing a 50% reduction in target optical density compared to no serum control wells. 146
Quantification of anti-CtxB and anti-OSP responses
147
Anti-CtxB and anti-OSP responses were measured by previously described isotype-specific 148
ELISAs [32, 33] . Briefly, 96-well plates (Nunc) were coated with 1 µg/mL solution of bovine GM1 149 monosialoganglioside (Sigma) in 50mM carbonate buffer overnight. Next, 1µg/mL CtxB in 0.1% 150 BSA/PBS purified from the classical Inaba strain 569B (List Biological Laboratories) was layered 151 onto the GM1-coated wells. Wells were blocked with a 1% BSA/PBS mixture after which 1:50 152 dilutions of the mouse serum samples were loaded into each well. Goat anti-mouse IgA, IgG or 153
IgM secondaries conjugated to HRP (Southern Biotechnology) were then added at a 154 concentration of 1µg/mL in 0.1% BSA/0.05% Tween/PBS and incubated for 90 minutes. Detection 155 was performed by adding an ABTS/H2O2 mixture to the wells and taking an absorbance 156 measurement at 405nm with a Vmax microplate kinetic reader (Molecular Devices Corp., 157
Sunnyvale, CA). Plates were read for 5 min at 30 s intervals, and the maximum slope for an optical 158 density change of 0.2 U was reported as millioptical density units per minute (mOD/min). Results 159 were normalized using pooled control serum from mice previously immunized against cholera and 160 reported as ELISA Units as previously described [32] . Anti-OSP responses were measured and 161 reported similarly to anti-CtxB responses, only instead of CtxB, purified OSP:BSA from either 162 PIC018 or PIC158 (1 µg/mL) was used to coat plates as previously described [34] . Additionally, 163 OSP ELISAs were carried out with 1:25 dilutions of the serum samples. 164
Infant mouse challenge assay
165
The infant mouse survival challenge was adapted from previous reports to optimize the dosage 166
for HaitiWT and to include more frequent monitoring intervals [31, 32] . Pregnant dams were singly 167 8 housed at E18-19 for delivery. At P3 (third day of life), pups were orally inoculated with 10 7 CFU 168 V. cholerae in 50µL LB and returned to their dam. Infected pups were monitored every 4-6 hours 169 for onset of diarrhea and reduced body temperature. Once symptoms appeared, monitoring was 170 increased to every 30 minutes until moribundity was reached, at which point pups were removed 171 from the nest and euthanized by isoflurane inhalation followed by decapitation for dissection and 172 CFU plating of the small intestine on LB + Sm/X-gal. Pups that were alive at 48 hpi were deemed 173 protected from the challenge. Cross-fostering was performed by transferring up to half of a litter 174 between dams on the first day of life (P1). Fostering was maintained for at least 48 hours before 175 infection to fully replace the milk from the original dam. We excluded rejected pups from analyses 176 due to our inability to attribute mortality to infection alone. 177 4-week-old C57BL/6 mice that were all immunized with HaitiV. We generally followed the multi-210 dose oral immunization scheme previously used in this model, which included eight doses of 211 1x10 9 CFU vaccine over eight weeks [36, 37] . After this vaccination regimen, the mice in cohort 2 212 were mated and vaccine-induced protective immunity was assessed in the progeny (Fig 1A) . 213
Statistical analysis
Based on fecal CFU, all animals in both cohorts were stably colonized with high levels of either 214 vaccine strain (Fig 1B) . No adverse effects of long-term colonization with HaitiV or CVD103-HgR 215
were noted, and all mice gained weight over the course of the study (Fig 1B) . Fecal shedding 216 and presumably intestinal colonization of HaitiV in cohort 2 was eliminated after these dams were 217 used to cross-foster pups born to specified-pathogen free (SPF) control mice (described below), 218
suggesting that a normal microbiota can outcompete HaitiV. 219
HaitiV immunization elicits robust serum antibodies targeting V. cholerae 220 Serum samples from the immunized mice were used to quantify antibodies targeting several V. 221 cholerae factors thought to play roles in protection from cholera. One of these metrics, the 222 vibriocidal antibody titer, is a validated correlate of protection in vaccinated humans [39] [40] [41] [42] . In 223 cohort 1, all mice immunized with HaitiV or CVD-103HgR seroconverted within 2 weeks and 224 developed vibriocidal titers consistent with those reported in human studies for live OCVs (Fig 2) 225 [41, 43] . Furthermore, HaitiV and CVD-103HgR elicited comparable vibriocidal titers. 226
In cohort 2, HaitiV immunization of C57BL/6 mice also induced high vibriocidal titers to Ogawa 227 and Inaba target strains (Fig 2C) . Isotype-specific levels of antibodies targeting Ogawa and Inaba 228 O-antigen specific polysaccharide (OSP), and the B-subunit of CT (CtxB) were also measured 229 since they also likely contribute to immunity to cholera [39] . Although we did not measure Day 1 230 titers in cohort 2, measurements from naïve GF C57BL/6 mice and baseline measurements from 231 cohort 1, and Day 1 of HaitiV-inoculated C57BL/6 mice in a later cohort (Fig S2) showed 232 undetectable levels of vibriocidal antibodies (Fig 2A, S2) . The cohort 2 mice developed strong 233 anti-Ogawa and anti-Inaba OSP responses (Fig 3, Table S2 ). The anti-Ogawa OSP titers were 234 generally higher than those targeting Inaba OSP, likely reflecting the fact that HaitiV is an Ogawa 235 strain. All mice in cohort 2 also developed high levels of anti-CtxB IgA, IgG and IgM antibodies 236 (Fig 4, Table S1 ). The 100% seroconversion rate and general increase over time of all three 237 HaitiV-immunized or control dams with lethal doses of different wild type V. cholerae strains. This 243 assay has been used to study passive immunity elicited by cholera vaccines, but has not been 244 characterized in vaccinated GF mice [31, 32] . Initially, we optimized this assay with litters from 245 SPF C57BL/6 control mice. Three or four-day old pups were inoculated with 10 7 or 10 8 CFU of 246
HaitiWT, the virulent strain from which HaitiV was derived and returned to their dams for 247 monitoring (Fig 5A) . Infected pups from both groups rapidly developed signs of dehydrating 248 diarrheal disease, including accumulation of nest material on their anogenital regions, lethargy, 249 skin tenting and hypothermia. All infected pups died by 48 hours post inoculation (hpi), with a 250 median time to moribundity of ~23-26 hpi (Fig 5B) . At the time of death, all pups were heavily 251 colonized, with >10 7 CFU/small intestine ( Fig 5C) , and had swollen ceca, another hallmark of 252 productive cholera infection in mammalian models [30, 44] . Since there were no significant 253 differences in survival or bacterial loads in mice challenged with either 10 7 or 10 8 CFU, the smaller 254 dose was used in subsequent experiments (Fig 5B) . Diarrhea and death in this model were 255 entirely dependent on CT; infant mice inoculated with HaitiWT ΔctxAB or HaitiV were completely 256 healthy at 48 hpi, despite sustained intestinal colonization (Fig 5C) . 257
We next mated HaitiV-immunized animals from cohort 2 with age-matched GF male mice, thereby 258 preserving their colonization with HaitiV. When challenged with HaitiWT, none of the 16 pups born 259 to HaitiV-immunized dams developed signs of diarrhea or died by 48 hpi; in stark contrast, all 260 pups born to non-immunized dams died within ~30 hpi (Fig 6A, left) . There was a marked ~5,000-261 fold reduction in the intestinal load of HaitiWT in pups born to immunized versus control dams 262 (Fig 6A, right) . The pups of the immunized dams remained healthy for at least 2 weeks post-263 challenge, even though there were still detectable but very low levels of HaitiWT in their intestinal 264 homogenates (Fig S1) . Thus, oral immunization with HaitiV elicits an immune response that 265 provides potent protection in nursing pups from diarrheal disease, death and V. cholerae intestinal 266 colonization. 267
Pups of HaitiV-immunized dams were similarly challenged with heterologous V. cholerae strains, 268 to test the serotype and serogroup specificity of protection engendered by oral immunization with 269
HaitiV. The additional challenge strains included an O1 Inaba strain (N16961) that has been used 270 as the challenge strain in several human volunteer cholera studies [43, 45] and the serogroup 271 O139 strain MO10, which was isolated during the 1992 O139 outbreak in India. Most pups from 272
HaitiV-immunized dams were protected from N16961 V. cholerae challenge (7/10 survival at 48 273 hpi, Fig 6B) . Despite the clinical protection, there was a much less dramatic reduction in the 274 intestinal burden of N16961 (~20-fold) compared to that observed with HaitiWT challenge, 275 indicating serotype-specific responses play an important role in limiting colonization. Surprisingly, 276 pups challenged with MO10 also exhibited some protection, but there was no concomitant 277 reduction in the intestinal burden of this O139 strain (Fig 6C) . Together, these observations 278 demonstrate that animals can exhibit protection from death despite relatively robust colonization, 279
suggesting that protection from disease may result from immunity targeting factors such as CtxB, 280 in addition to those that impede colonization. Since our earlier studies indicated that HaitiV itself can mediate rapid protection against cholera 285 independent of an adaptive immune response, it was important to investigate whether pups 286 nursed by HaitiV immunized dams were colonized with the vaccine strain. Extensive plating of 287 intestinal samples from the >50 pups used for survival assays (limit of detection = 50 CFU/small 288 13 bowel) did not reveal any HaitiV CFU in the pups reared by HaitiV-shedding dams. Thus, vaccine 289 strain transmission and its probiotic effects are almost certainly not the explanation for the potent 290 protection observed in nursing pups. 291
Cross-fostering experiments were undertaken to investigate the likely passive nature of the 292 protection. P1 pups born to SPF dams were transferred to and reared by HaitiV-immunized dams 293 and then challenged 2 days later with HaitiWT (Fig 5A, between P1-P3 ). All pups crossed-fostered 294 by immunized dams were protected (100% survival at 48 hpi) and nearly all had marked 295 reductions (~1,000 fold) in their intestinal HaitiWT burdens (Fig 7A) . These observations mirror 296 the challenge studies presented above (Fig 6A) , indicating passive immunity from milk accounts 297 for the protection that HaitiV-immunized dams bestow to their progeny. Conversely, when pups 298 born to HaitiV-immunized dams were cross-fostered by SPF (non-vaccinated) dams, all 299 succumbed to HaitiWT challenge, albeit with an increase in median survival time (by ~6-hour) and 300 had high HaitiWT intestinal burdens (Fig 7B) . The modest extension in survival time in these mice 301 may be due to trans-placentally derived immunity or residual milk from the HaitiV-immunized dam. 302
303
A single oral dose of HaitiV is sufficient to elicit protective immunity 304 Finally, to investigate whether the multiple dose regimen was necessary for stimulating protective 305 immunity, we tested whether a single oral dose of HaitiV stimulated protective immune responses 306 in female GF C57BL/6 mice (n=4). Like our studies with the multiple dose regimen, a single dose 307 of HaitiV led to sustained colonization in the mice (Fig S2) . HaitiV induced vibriocidal antibody 308 titers comparable in magnitude to those from serially immunized mice (Fig 2C) . Litters from singly-309 immunized mice were also completely protected from disease resulting from HaitiWT challenge, 310 phenocopying pups from the first cohorts (Fig S2) . serogroup, and to a lesser extent serotype are major determinants of protection against V. 331 cholerae challenge [39, 46] . Although it is thought that exposure to Inaba strains is more cross-332 protective than exposure to Ogawa strains, the relative potency of Inaba versus Ogawa vaccines 333 in eliciting dual protection against both O1 serotypes requires further definition, as it has been 334 suggested that both Ogawa and Inaba vaccine strains are good candidates for development [4-335 7] . A mixture of Ogawa and Inaba serotypes either as distinct strains or one bivalent strain 336 15 (serotype Hikojima) may be beneficial in broadening the breadth of the immune response to HaitiV 337 [47, 48] . 338
The modest protection that HaitiV immunization provided against V. cholerae O139 was 339 unexpected. The epidemiology of the original O139 outbreak and experimental studies in rabbits 340 demonstrate a lack of cross-protection between the two serogroups [14, 15, 39] . Notably, although 341 pups born to HaitiV-immunized dams and challenged with MO10 survived longer than pups born 342 to non-immunized dams, there was little difference in the MO10 intestinal colonization between 343 these groups (Fig 6C) . The discrepancy between clinical protection and relatively robust 344 colonization suggests that HaitiV stimulates immune responses to V. cholerae factors, like CT, 345 that may contribute to disease but not directly to colonization. The capacity of live OCVs to induce 346 immune responses to in vivo-expressed antigens, including CtxB, is a property that heightens the 347 appeal of live vs killed OCVs [27, 49] . 348
Although GF mice enabled us to test the protective efficacy of a candidate live OCV, the absence 349 of the microbiota and resulting improper immune development in these mice, are important 350 caveats to consider. The GF model does not recapitulate the competitive microbial environment 351 that live OCVs will encounter in the human host. We observed similar prolonged shedding 352 patterns for both CVD-103HgR and HaitiV in the GF mice (Fig 1) , yet CVD-103HgR is known to 353 be shed by human volunteers at a low frequency for a short period [25, 50] cholerae outer membrane vesicles [51, 52] . The streptomycin-treated mouse model of V. cholerae 360 colonization, which allows for temporary intestinal colonization, may also be useful to investigate 361 the duration of colonization required for immunity [53] . Ultimately, the capacity of HaitiV to 362 colonize the intestine and the relationship between colonization and protective immunity will need 363 to be defined in human volunteers. 364
The immunogenicity of live OCVs in mice has only been investigated in GF animals because adult 365 mice with intact microbiota are refractory to intestinal V. cholerae replication and colonization. 366
However, previous studies of live OCVs in GF mice only analyzed immune correlates of protection 367
and not protection against challenge [36, 37] . The combination of the neonatal survival assay with 368 the oral GF vaccination model builds on existing knowledge of these mice to assay both the 369 immunogenicity and protective efficacy of live OCV candidates [38] . This model may be a useful 370 addition to existing approaches that probe the molecular bases of vaccine-mediated mucosal 371 protection against pathogens, a topic with significant translational potential that remains poorly 372 understood [52, 54] . A recent report employing a similar maternal-infant transmission model in the 373 context of intraperitoneally-delivered heat-killed Citrobacter rodentium highlights the versatility of 374 assessing vaccine protective efficacy using the infant progeny of immunized animals as readouts 375
[55]. The broad availability of genetically engineered mice and the relative ease of GF-derivation 376 provides a powerful opportunity to leverage both host and bacterial genetics to explore how live-377
OCVs can be optimized to better defend against this ancient pathogen. 
